Search results (110)
« Back to PublicationsEtrasimod Real-World Experience in Ulcerative Colitis: A multicentre cohort study
Journal article
Vayreda E. et al, (2026), JOURNAL OF CROHNS & COLITIS, 20
Factors associated with hospitalisations, emergency visits and related costs in inflammatory bowel disease: insights from the TrueColours-IBD digital monitoring programme in Oxford
Conference paper
Fierens L. et al, (2026), JOURNAL OF CROHNS & COLITIS, 20
A single centre real-world study of Risankizumab in Crohn's disease
Conference paper
Tan CK. et al, (2026), JOURNAL OF CROHNS & COLITIS, 20
Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.
Journal article
Lee SD. et al, (2025), The American journal of gastroenterology, 120, 2857 - 2866
Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.
Journal article
Moran GW. et al, (2025), BMJ open, 15
Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers.
Journal article
Dubinsky M. et al, (2025), The American journal of gastroenterology
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study.
Journal article
Radia C. et al, (2025), Journal of Crohn's & colitis, 19
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.
Journal article
Regueiro M. et al, (2025), Journal of Crohn's & colitis, 19
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey.
Journal article
Fiorino G. et al, (2025), Journal of Crohn's & colitis, 19
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
Journal article
Fiorino G. et al, (2025), Journal of Crohn's & colitis, 19
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.
Journal article
Clemow DB. et al, (2025), Journal of patient-reported outcomes, 9
Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis.
Journal article
Panaccione R. et al, (2025), Crohn's & colitis 360, 7
Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres.
Journal article
Young D. et al, (2025), Drugs in context, 14
Ozanimod: real world outcomes from three UK centres
Conference paper
Choon XY. et al, (2025), GUT, 74, A71 - A72
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Journal article
Thomas T. et al, (2024), Nature Immunology, 25, 2152 - 2165